Canagliflozin in der Monotherapie: Klinische Studiendaten bei Diabetes mellitus Typ 2

Schlüsselwörter

Canagliflozin - Monotherapie - Typ-2-Diabetes - Blutzuckereinstellung - Blutdruck - SGLT-2-Inhibition

Keywords

canagliflozin - monotherapy - type 2 diabetes - glycaemic control - blood pressure - SGLT-2 inhibition

• Literatur

• 1 Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013; 27: 280-286
• 2 Chan HW, Ashan B, Jayasekera P et al. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'. Diabetes Metab Syndr 2012; 6: 224-228
• 3 Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 392-402
• 4 Deshmukh AB, Patel MC, Mishra B. SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus. Ren Fail 2013; 35: 566-572
• 5 Ferrannini E, Cushman WC. Diabetes and hypertension: The bad companions. Lancet 2012; 380: 601-610
• 6 Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012; 9: 117-123
• 7 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
• 8 Kassenärztliche Vereinigung Nordrhein (KVNO). Qualitätssicherungsbericht 2009: Disease-Management-Programme in Nordrhein. DMP Diabetes mellitus Typ 2. http://www.kvno.de/downloads/quali/qualbe_dmp09.pdf (letzter Zugriff 11.12.2013)
• 9 Komala MG, Panchapakesan U, Pollock C et al. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 2013; 22: 113-119
• 10 Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013; 9: 763-775
• 11 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2159-2219
• 12 Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840
• 13 Polidori D, Sha S, Mudaliar S et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study. Diabetes Care 2013; 36: 2154-2161
• 14 Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev 2013; 29: 347-356
• 15 Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672
• 16 Stenlöf K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382
• 17 UK Prospective Diabetes Study Group. Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. BMJ 1998; 317: 703-713
• 18 Vijan S, Hayward RA. Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care. Ann Intern Med 2003; 138: 593-602
• 19 Wilke T, Ahrendt P, Schwartz D et al. Inzidenz und Prävalenz von Diabetes mellitus Typ 2 in Deutschland. Eine Analyse auf Basis von 5,43 Mio. Patientendaten. Dtsch Med Wochenschr 2013; 1380: 69-75